{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041138","form_type":"8-K","ticker":null,"cik":"0001121702","company_name":"YIELD10 BIOSCIENCE, INC.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.445739+00:00","generated_at":"2026-06-04T05:11:56.929455+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Yield10 Bioscience receives Nasdaq deficiency notice; plans reverse stock split","bullets":["Nasdaq staff notified Yield10 on March 26, 2024 it is ineligible for a second 180-day bid price compliance period due to insufficient stockholders' equity.","Company does not meet the $5 million minimum stockholders' equity initial listing requirement for The Nasdaq Capital Market.","Yield10 must present its views to the Nasdaq Panel by April 2, 2024 and plans a special shareholder meeting on April 26, 2024 to approve a reverse stock split.","Stock continues trading on The Nasdaq Capital Market under symbol YTEN; no immediate delisting effect but compliance is uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041138","json":"https://secwatch.observer/filing/0001104659-24-041138.json","markdown":"https://secwatch.observer/filing/0001104659-24-041138.md","text":"https://secwatch.observer/filing/0001104659-24-041138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1121702/000110465924041138/0001104659-24-041138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1121702/000110465924041138/tm2410151d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:11:56.929455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b44f2a8e6697017ddd5d057ef5d4ec04f5923b1","claim":"YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity.","evidence_excerpt":"March 26, 2024, the Company received written notice (the “Notice”) from the Staff stating that the Company is not eligible for a second 180 day compliance period for the Minimum Bid Price Rule deficiency because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The Notice indicates that the Company must present its views with respect to this deficiency to the Panel in writing no later than April 2, 2024, which it intends to do. Among other measures, the Company intends to schedule a special meeting of its sha","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1121702/000110465924041138/0001104659-24-041138-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}